<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Medarex Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/medarex-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SEPR) Top Small-Cap Equity Funds &#8211; Mutual Fund Commentary</title>
		<link>http://www.stockbloghub.com/2009/10/16/sepr-top-small-cap-equity-funds-mutual-fund-commentary-2/17731</link>
		<comments>http://www.stockbloghub.com/2009/10/16/sepr-top-small-cap-equity-funds-mutual-fund-commentary-2/17731#comments</comments>
		<pubDate>Sat, 17 Oct 2009 00:04:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17731</guid>
		<description><![CDATA[Today we are featuring top-performing “Small-Cap&#8221; equity mutual funds, which primarily invest in equity securities of companies that have market capitalizations of less than $2 billion. Investors can find such funds by checking out the entire list of the Zacks #1 Rank Small-Cap Equity Funds. 2 Solid Picks Dean Small Cap Value A (DASCX) seeks long-term capital appreciation and secondarily, dividend income. The fund focuses on high-quality companies that are undervalued for transitory reasons in search of above-average returns. The fund may invest in equity securities of mid or large-cap companies, preferred stocks, or derivative instruments, such as put and call options and futures contracts, and in fixed-income securities Incorporatedluding corporate bonds. Unit holders have to make a minimum initial investment of $1,000 to enter this Zacks#1 Rank (“Strong Buy&#8221;) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/sepr-top-small-cap-equity-funds-mutual-fund-commentary-2/17731/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SEPR) Top Small-Cap Equity Funds &#8211; Mutual Fund Commentary</title>
		<link>http://www.stockbloghub.com/2009/09/23/sepr-top-small-cap-equity-funds-mutual-fund-commentary/15887</link>
		<comments>http://www.stockbloghub.com/2009/09/23/sepr-top-small-cap-equity-funds-mutual-fund-commentary/15887#comments</comments>
		<pubDate>Wed, 23 Sep 2009 20:09:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Charles River Laboratories International]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15887</guid>
		<description><![CDATA[Today we are featuring top-performing “Small-Cap&#8221; equity mutual funds, which primarily invest in equity securities of companies that have market capitalizations of less than $2 billion. Investors can find such funds by checking out the entire list of the Zacks #1 Rank Small-Cap Equity Funds. 3 Solid Choices Buffalo Small Cap (BUFSX) seeks long-term growth of capital. The fund targets companies with individual market capitalizations of $2 billion or less at the time of initial purchase. The fund primarily invests in common stocks, preferred stocks, convertible preferred stocks warrants and rights of domestic small-cap companies. As of March 2009, its portfolio turnover was 15%. Kent Gasaway has been lead manager at the fund since its inception in April 1998. Previously, Gasaway spent 10 years with Waddell &#38; Reed Mutual Funds ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/23/sepr-top-small-cap-equity-funds-mutual-fund-commentary/15887/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MEDX) Top Delaware Funds &#8211; Mutual Fund Education</title>
		<link>http://www.stockbloghub.com/2009/09/02/medx-top-delaware-funds-mutual-fund-education/14160</link>
		<comments>http://www.stockbloghub.com/2009/09/02/medx-top-delaware-funds-mutual-fund-education/14160#comments</comments>
		<pubDate>Wed, 02 Sep 2009 20:22:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14160</guid>
		<description><![CDATA[Delaware Trend A (DELTX) seeks long-term capital appreciation by primarily investing in small, growth-oriented or emerging companies. The fund uses a bottom-up approach to create a portfolio and normally maintains its position in a stock until it fully achieves its growth potential. It analyzes price-to-earnings ratios, estimated growth rates, market capitalization and cash flows to determine the attractiveness of a company. Medarex Inc. (MEDX), Sepracor Inc. (SEPR) and Abraxis BioScience Inc. (ABII) are among the fund’s key holdings. Delaware International Value Equity A (DEGIX) was incepted in October 1991. The investment seeks long-term growth without undue risk to principal. The fund invests primarily in equity securities of issuers from foreign countries but may invest more than 25% of assets in the securities of issuers located in the same country. As ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/medx-top-delaware-funds-mutual-fund-education/14160/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Buyout of Medarex Update</title>
		<link>http://www.stockbloghub.com/2009/08/28/bmy-bristol-myers-squibb-buyout-of-medarex-update/13807</link>
		<comments>http://www.stockbloghub.com/2009/08/28/bmy-bristol-myers-squibb-buyout-of-medarex-update/13807#comments</comments>
		<pubDate>Fri, 28 Aug 2009 23:03:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADC]]></category>
		<category><![CDATA[Agree Realty Corp.]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13807</guid>
		<description><![CDATA[Yesterday, Bristol-Myers Squibb Co. (BMY) announced that its cash tender offer to purchase all outstanding shares of common stock of Medarex Inc. (MEDX) expired on Aug. 26.  The tender offer was not extended, unlike the previous instance when the offer originally scheduled to close on August 24 was extended by two days. The cash tender offer saw 87.7% of Medarex shares outstanding, or a total of 119 million shares, being tendered. With an objective of acquiring the remaining Medarex stock, Bristol announced a subsequent offering period from yesterday until August 31, 2009, unless extended. The Bristol management believes that the completion of the deal would be hastened if more than 90% Medarex shares are tendered. Even if the new tender offer fails to attain this goal, the deal is expected ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/bmy-bristol-myers-squibb-buyout-of-medarex-update/13807/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Wider Label Approval for Bristol Myers Squibb Drug</title>
		<link>http://www.stockbloghub.com/2009/08/27/bmy-wider-label-approval-for-bristol-myers-squibb-drug/13696</link>
		<comments>http://www.stockbloghub.com/2009/08/27/bmy-wider-label-approval-for-bristol-myers-squibb-drug/13696#comments</comments>
		<pubDate>Fri, 28 Aug 2009 00:18:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13696</guid>
		<description><![CDATA[Bristol Myers Squibb Co. (BMY) yesterday announced the approval of a broader label for its rheumatoid arthritis drug Orencia by the U.S. Food and Drug Administration (FDA). The agency approved an addition to the label that supports the use of Orencia (abatacept) in patients suffering from moderate to severe rheumatoid arthritis, duration of which is less than or equal to two years. The drug that recorded global sales of $129 million in 2008 is designed to reduce symptoms of rheumatoid arthritis. However, it should not be administered along with tumor necrosis factor (TNF) antagonists and is not recommended for use in tandem with other biologic rheumatoid arthritis therapies. As a reminder, the drug was initially approved by the FDA in late 2005 and made commercially available in the U.S. in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/bmy-wider-label-approval-for-bristol-myers-squibb-drug/13696/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Working on Medarex</title>
		<link>http://www.stockbloghub.com/2009/08/21/bmy-bristol-myers-working-on-medarex-analyst-blog/13058</link>
		<comments>http://www.stockbloghub.com/2009/08/21/bmy-bristol-myers-working-on-medarex-analyst-blog/13058#comments</comments>
		<pubDate>Fri, 21 Aug 2009 19:06:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13058</guid>
		<description><![CDATA[Yesterday, Bristol-Myers Squibb Co. (BMY) extended its cash tender offer to purchase all outstanding shares of Medarex Inc. (MEDX) by two days to Aug. 26. Bristol-Myers offered to buy Medarex for $16 per share, or $2.1 billion in July. However, less than 9% of Medarex&#8217;s outstanding shares have been tendered till now. Last week, antitrust regulators approved the deal. With the acquisition of Medarex, Bristol-Myers will get the UltiMAb Human Antibody Development System, which produces high affinity, human antibodies for use in a broad range of therapeutic areas Incorporatedluding immunology and oncology. It will also obtain Medarex’s next-generation Antibody-Drug Conjugate  technology, which is a novel and proprietary platform that could open new fields in cancer treatment. Medarex’s has seven antibodies in clinical trials under its sole funding and is developing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/21/bmy-bristol-myers-working-on-medarex-analyst-blog/13058/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

